Language:
  
[Sign in] [Register]   

EIAab logo

EIAab news detail, please contact eiaab@eiaab.com if you have any questions about online orders and payment.
Evaluation of the possible nephroprotective effects of vitamin E and rosuvastatin in amikacin-induced renal injury in rats
Update time:2017-10-31 14:21:00   【 Font: Large  Medium Small


Abstract

Amikacin (AMIK) is an aminoglycoside antibiotic that possesses considerable nephrotoxic adverse effects. This study examined the protective effects of vitamin E (VIT. E) or rosuvastatin (ROSU) against AMIK-induced nephrotoxicity. For this purpose, eight groups of rats were used. Two control groups received saline and vehicle, AMIK group (1.2 g/kg, i.p.), VIT. E group (1000 mg/kg; p.o.), ROSU group (10 mg/kg; p.o.), AMIK + VIT. E group, AMIK + ROSU group, and combination group. The results showed that AMIK significantly increased serum levels of urea and creatinine. Meanwhile, serum levels of total protein and albumin were decreased. The kidney content of malondialdehyde was increased, whereas glutathione content and catalase activity were decreased. Tumor necrosis factor-α and nuclear transcriptional factor levels were increased. Conversely, administration of VIT. E and/or ROSU with AMIK ameliorated such damage and reduced DNA fragmentation, apoptosis, and necrosis. In conclusion, co-administration of VIT. E, ROSU, or their combination alleviated AMIK-induced nephrotoxicity.


Cited products
Source:Journal of Biochemical and Molecular Toxicology      by A Selim, M M. khalaf, A M. Gad, et al.
Hot Genes
Atf2 ASPRO ACE ALCAM C19orf80 Trap1a Gdf5
Top Searches
Ubiquitin-protein ligase metalloproteinase Ubiquitin ELISA Tumor necrosis Alpha Asprosin TRAP1A
Why choose EIAAB
Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
Further Information
About us Protein center Bank account Distributors Terms & Conditions Career eiaab.com.cn

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

鄂ICP备10015095号-1

鄂公网安备 42018502005535号

Twitter